Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

Aya F, Fernández-Martínez A, Gaba L, Victoria I, Tosca M, Carrera C, Prat A, Arance A.

Immunotherapy. 2016 Jun;8(6):687-92. doi: 10.2217/imt-2015-0025. Epub 2016 Apr 26.

PMID:
27115320
2.

Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.

Day F, Kumar M, Fenton L, Gedye C.

J Immunother. 2017 Jan;40(1):36-38.

PMID:
27684455
3.

Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.

Spain L, Larkin J.

Immunotherapy. 2016 Jun;8(6):677-9. doi: 10.2217/imt.16.6. No abstract available.

4.

Safety of immune checkpoint inhibitors in Chinese patients with melanoma.

Wen X, Wang Y, Ding Y, Li D, Li J, Guo Y, Peng R, Zhao J, Zhang X, Zhang XS.

Melanoma Res. 2016 Jun;26(3):284-9. doi: 10.1097/CMR.0000000000000256.

PMID:
27116334
5.

Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.

Zecchini JM, Kim S, Yum K, Friedlander P.

J Immunother. 2018 Jan;41(1):39-41. doi: 10.1097/CJI.0000000000000184.

PMID:
28926356
6.

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN.

Ann Oncol. 2018 Jan 1;29(1):250-255. doi: 10.1093/annonc/mdx642.

7.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
8.

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.

La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.

Pharmacotherapy. 2015 Oct;35(10):963-76. doi: 10.1002/phar.1643. Review. Erratum in: Pharmacotherapy. 2015 Dec;35(12):1205.

PMID:
26497482
9.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.

Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.

PMID:
26115796
10.

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L.

J Immunother. 2016 Nov/Dec;39(9):379-382.

11.

[Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].

Robert C, Mateus C.

Bull Acad Natl Med. 2014 Feb;198(2):297-308. French.

PMID:
26263705
12.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators.

N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.

13.

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.

Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC; German Dermatooncology Group (DeCOG).

Eur J Cancer. 2017 Apr;75:24-32. doi: 10.1016/j.ejca.2016.12.038. Epub 2017 Feb 16.

PMID:
28214654
14.

Pembrolizumab use for the treatment of advanced melanoma.

Specenier P.

Expert Opin Biol Ther. 2017 Jun;17(6):765-780. doi: 10.1080/14712598.2017.1309388. Epub 2017 Apr 3.

PMID:
28323504
15.

Programmed death-1 & its ligands: promising targets for cancer immunotherapy.

Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN.

Immunotherapy. 2015;7(7):777-92. doi: 10.2217/imt.15.49. Epub 2015 Aug 7. Review.

PMID:
26250412
16.

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD.

JAMA Oncol. 2015 Jul;1(4):433-40. doi: 10.1001/jamaoncol.2015.1184.

PMID:
26181250
17.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM.

PLoS One. 2015 Oct 1;10(10):e0139438. doi: 10.1371/journal.pone.0139438. eCollection 2015.

18.

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.

Simeone E, Ascierto PA.

J Immunotoxicol. 2012 Jul-Sep;9(3):241-7. doi: 10.3109/1547691X.2012.678021. Epub 2012 Apr 23. Review.

PMID:
22524673
19.

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Buchbinder EI, Desai A.

Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. Review.

20.

Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.

Maul LV, Weichenthal M, Kähler KC, Hauschild A.

J Immunother. 2016 May;39(4):188-90. doi: 10.1097/CJI.0000000000000118.

PMID:
27023060

Supplemental Content

Support Center